Cargando…
DIPG-61. Preclinical efficacy of combined radiotherapy with venetoclax treatment in targeting diffuse midline gliomas
BACKGROUND: H3K27M diffuse midline gliomas (DMGs) are highly aggressive pediatric tumors of pons, thalamus or spinal cord. The only standard-of-care for DMGs is radiation therapy (RT) since the anatomical location of such tumors does not allow surgical resection. Tumor response to RT is at best tran...
Autores principales: | Madhavan, Krishna, Balakrishnan, Ilango, Lakshmanachetty, Senthilnath, Pierce, Angela, Sanford, Bridget, Fosmire, Susan, Elajaili, Hanan, Walker, Faye, Wang, Dong, Nozik-Grayck, Eva, Mitra, Siddhartha, Dahl, Nathan, Vibhakar, Rajeev, Venkataraman, Sujatha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165325/ http://dx.doi.org/10.1093/neuonc/noac079.118 |
Ejemplares similares
-
DIPG-56. Development and application of a novel antibody against CD99 as a therapeutic strategy in Diffuse Midline Glioma
por: Venkataraman, Sujatha, et al.
Publicado: (2022) -
DIPG-34. SUPER ELONGATION COMPLEX AS A TARGETABLE DEPENDENCY IN H3K27M+ DIFFUSE MIDLINE GLIOMA
por: Dahl, Nathan, et al.
Publicado: (2020) -
DIPG-73. SENESCENCE ASSOCIATED SECRETORY PHENOTYPE AS A MECHANISM OF RESISTANCE AND THERAPEUTIC VULNERABILITY IN BMI1 INHIBITOR TREATED DIPG
por: Balakrishnan, Ilango, et al.
Publicado: (2020) -
DIPG-32. PRECLINICAL TESTING OF THE EFFICACY AND SAFETY OF CRISPR/CAS9 GENE EDITED CAR-T CELL THERAPY FOR DIFFUSE MIDLINE GLIOMA (DMG)
por: Balakrishnan, Ilango, et al.
Publicado: (2023) -
DIPG-39. New preclinical models for Diffuse Midline Glioma
por: Klenner, Marbod, et al.
Publicado: (2022)